InfuSystem Holdings, Inc. filed a Form 8-K on November 3, 2026, disclosing that the company has postponed its previously scheduled release of financial results for the third quarter ended September 30, 2026.

Key Highlights

  • Postponement announced: InfuSystem disclosed it has postponed its third-quarter financial results release, which had been scheduled for November 3, 2026.
  • Period covered: The delayed results pertain to the quarter ended September 30, 2026.
  • Disclosure type: The announcement was made under Regulation FD (Item 7.01) via a press release furnished as Exhibit 99.1.
  • Exchange and ticker: The company's common stock (par value $0.0001 per share) trades on NYSE American:INFU.
  • Signatory: The filing was signed by Carrie Lachance, Chief Executive Officer and Director.

InfuSystem Delays Third-Quarter 2026 Financial Results Without Specifying New Date

According to the filing, InfuSystem Holdings, Inc. (NYSE American:INFU) issued a press release on November 3, 2026, announcing the postponement of its third-quarter financial results, which had previously been scheduled for release that same day. The company did not specify a new release date within the body of the 8-K filing itself. The press release detailing the announcement was furnished as Exhibit 99.1 to the Current Report.

The disclosure was made under Item 7.01, Regulation FD, of the Form 8-K. The filing notes that the information furnished under that item "shall not be deemed 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference" into the company's other filings under the Securities Act of 1933 or the Securities Exchange Act of 1934. No financial figures, reasons for the postponement, or revised scheduling details were included in the 8-K text itself.

InfuSystem Holdings, Inc. is incorporated in Delaware and maintains its principal executive offices at 3851 West Hamlin Road, Rochester Hills, Michigan 48309. The filing was signed by Carrie Lachance, identified as Chief Executive Officer and Director, and dated November 3, 2026.

What Was Disclosed

InfuSystem filed an 8-K on November 3, 2026, reporting the postponement of its Q3 2026 earnings release under Regulation FD. No new release date, financial figures, or explanation for the delay were provided in the filing text.